


<https://senexbio.com>



Making Cancers Curable



# Senex Biotechnology Overview

Senex has created a unique new class of drugs that suppress cellular reprogramming that plays a key role in treatment resistance and metastasis of cancers, as well as in other diseases.

Senex is developing our lead drug candidate for treatment of the presently incurable metastatic prostate cancer.




# Overcoming Resistance

While remarkable targeted cancer drugs have been developed, their effects are typically short-lived. Almost all tumors stop responding to treatments and the cancers continue progressing.

## Response of a melanoma patient treated with a targeted drug (Vemurafenib)

before treatment      after 15 weeks      after 23 weeks



Wagle N et al. JCO 2011;29:3085-3096

Most cancers treated with different classes of drugs eventually develop drug resistance and cannot be cured.

**Introducing the Senex Biotechnology solution.**




# Success in Prostate Cancer


In **prostate cancer**, principal treatments cut off access to the male hormone androgen that cancer cells need to grow, but many tumors adapt themselves to grow without it. As a result, leading prostate cancer drugs only prolong patients' lives by several months.

Our drug stops the growth of advanced prostate cancers under the conditions of androgen deprivation and even makes them disappear. It also suppresses prostate cancer growth in the **bone**, the principal cause of prostate cancer lethality.

**Tumor from a patient who failed all the approved treatments responds to Senex's drug**



**Cures achieved for the first time in a notoriously resilient prostate cancer model**



# Key Highlights



Ready for manufacturing and preclinical GLP safety studies. Preliminary studies show safety in mice and monkeys. Under review for licensing by major pharma companies.



14 competitive grant awards, including an active \$2M from the National Cancer Institute. Pending \$3M NCI Bridge Award.



Successfully outlicensed previous drug technology candidate for development.



8 issued and 8 pending U.S. patents & corresponding patents in other countries, covering the composition-of-matter of Senex's compounds and the uses of **any** Mediator kinase inhibitors for different clinical applications (including prostate and breast cancer).



We anticipate reaching clinical proof-of-concept in advanced prostate cancer in 3-4 years making Senex an acquisition target by big pharma.

# Meet The Team



**Igor Roninson, PhD, Founder, President, Chief Scientific Officer, Board Chair** | Dr. Roninson, a winner of AACR Award for Meritorious Achievement in Cancer Research and other major awards, is the Director of Center for Targeted Therapeutics at the University of South Carolina. Holder of 47 issued US patents (H-index 79).



**George Wilding, MD, Chief Medical Officer** | Dr. Wilding is an expert on prostate cancer and new drug development. Former Vice President and Deputy Chief Academic Officer at MD Anderson Cancer Center and Director of Carbone Comprehensive Cancer Center at the University of Wisconsin.



**Mengqian Chen, PhD, Director of Research** | Dr. Chen, who leads the team of Senex researchers, is an inventor of Senex's key patents and serves as the Principal Investigator on Senex's grants from NIH.



**Karthik Gopalakrishnan, PhD** | Dr. Gopalakrishnan leads Senex's corporate relationships, strategic planning and business development. In his Licensing office positions at Duke and University of Alabama, completed over 150 licensing transactions with a deal value over \$250M.



# Experienced Board

**Robert (Bob) Bonczek, JD, MBA** | Mr. Bonczek is founding partner of Aspentree Capital, a boutique investment company. President and CFO of MedBlue Incubator. Served as the CFO and/or President at various other companies including B3Bio, C2 Regenerate and Trimeris; Board member of about 10 companies.

**Dani Bolognesi, PhD** | Dr. Bolognesi is Founder, CEO and CSO at Trimeris, Inc., a public company that developed Fuzeon®, a first-in-class HIV fusion inhibitor, in collaboration with Hoffmann-La Roche. CEO and Chairman of b3Bio, Inc; CEO, Enci Therapeutics, Inc.; and CEO, C2 Regenerate, Inc and CSO of Istari Oncology Inc. Professor Emeritus at Duke University.

**Richard Davidson, PhD** | Dr. Davidson is former Executive Director of the Kimmel Cancer Center, Thomas Jefferson University and Endowed Chair and Head of the Department of Molecular Genetics, University of Illinois at Chicago. Board Member and Chief Scientific Advisor, Tyton Biosciences.

# Senex's Advantages

Our drugs work when other drugs stop working.



Issued patents block competition for the treatment of prostate and breast cancers.

High target selectivity = greater potency = reduced toxicity.



Preclinical and clinical experience that positions us for success.

# Investment Opportunity

Senex Biotechnology, Inc. is seeking a total of **\$10-12M** (flexible to the form of investment) to fuel the development of our leading drug candidate.

With a \$10-12M fundraise (which may be supplemented by \$3M from NCI Phase IIb Bridge Award), Senex will have sufficient capital to carry out Phase I/II clinical trials and approach clinical proof-of-concept.

## Use of funds:



**75%**

Product development



**10%**

R&D



**15%**

Key hires



Igor Roninson

roninson@senexbio.com | (518) 727-5152 | <https://senexbio.com>